Search

  1. About ProQR Therapeutics

    Page

    An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.

    In front of the entrance of the ProQR office

  2. ProQR founding story

    Page

    When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.

    Daniel de Boer, CEO of ProQR Therapeutics

  4. ProQR Analyst Event

    Webcast

    During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

  5. ProQR Update August 2022

    Community news

    … ProQR Update August 2022 Announced today (August 11, 2022), ProQR will focus exclusively on the development of the … from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 …

    Axiomer RNA editing platform technology

  6. Building an Inclusive ProQR

    Blog

    Pride month at ProQR is an opportunity to celebrate and thank all of the LGBT+ people in our communities, including our employees, scientists, and doctors that made our research possible.

    Rainbow image with text We Wish You A Happy Pride Month!

  8. ProQR Therapeutics Virtual R&D Event 2023

    Webcast

    On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.

  10. ProQR recognised as a Great Place To Work

    News update

    In April 2025, ProQR received the Great Place To Work (GPTW) certification following the results of the employee survey from GPTW Netherlands.

    ProQR recognised as a Great Place To Work